ARTICLE | Company News
Veracyte sales and marketing update
June 2, 2014 7:00 AM UTC
Veracyte launched Afirma Malignancy Classifiers in the U.S. to provide preoperative information to help guide surgical strategy in patients with thyroid nodules. Afirma Malignancy Classifiers comprises genomic tests to identify medullary thyroid cancer (MTC) and the BRAF gene mutation. The product will be offered as part of Veracyte's Afirma Thyroid FNA Analysis, which combines an initial review of thyroid nodule fine needle aspiration (FNA) samples by expert cytopathology assessment with Veracyte's Afirma Gene Expression Classifier to clarify any inconclusive results. ...